NCT03239899View on ClinicalTrials.gov

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
HIV Infections
Interventions
DRUG

Pembrolizumab

Participants will receive one dose of 2mg/kg of pembrolizumab IV at Week 0.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT03239899 - PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection | Biotech Hunter | Biotech Hunter